What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis? Commentary

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 2, Issue 12, 2005, Pages 564-565

  Travis, Simon ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Mesalazine; Remission; Ulcerative colitis

Indexed keywords

MESALAZINE; OLSALAZINE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HUMAN; INTESTINE MUCOSA; MAINTENANCE DRUG DOSE; META ANALYSIS; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; REMISSION; SHORT SURVEY; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 33644997708     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0336     Document Type: Short Survey

References (6)

1. Sutherland L et al. (2002) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 4: CD000544
2. Bebb JR and Scott BB (2004) Systematic review: How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 20: 143-149
3. Hanauer SB et al. (2005) Efficacy and safety of mesalazine 4.8 g/day (800 mg tablet) compared with 2.4 g/day (400 mg tablet) in treating moderately active ulcerative colitis: ASCEND II study [abstract]. Gut 53 (Suppl 2): A3
4. Travis SPL et al. (1994) The optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 35: 1282-1286
5. Frieri G et al. (2005) Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 37: 92-96
6. Kane S et al. (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114: 39-43